Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
MIST compared with AQST: revenue, margins and what each company keeps, and the suppliers and customers both name
MIST
Milestone Pharmaceuticals Inc.
Change
Mkt cap
Revenue
Revenue
AQST
Aquestive Therapeutics, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
MIST
Milestone Pharmaceuticals Inc.
vs
AQST
Aquestive Therapeutics, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Earnings history
Desk
News
Calendar
Saved
Search
Earnings history
last 4 reports each · paired by recency
Method
›
MIST
1 of 4 reports
0 of 1
at or beyond implied
Report
implied
realized
× implied
Q2 FY26
±57.2%
▼
−11.42%
×0.20
AQST
1 of 4
at or beyond implied
Report
implied
realized
× implied
Q2 FY26
±12.4%
▼
−4.08%
×0.33
May 14 '26
±7.7%
▲
+14.53%
×1.88
= implied
MIST realized, solid
AQST realized, hatched
One scale, both sides: full bar = 58%
× = |realized| ÷ implied
Source: market data
Q1 FY26
±14.1%
▼
−2.52%
×0.18
Q3 FY25
±16.2%
▲
+2.17%
×0.14
MIST
Milestone Pharmaceuticals Inc.
Change
0.73
▼
−7.26%
· post 0.73
Mkt cap
$90.9M
Revenue
$559,000
Q2 FY26
Revenue
—
AQST
Aquestive Therapeutics, Inc.
Change
3.89
▼
−3.79%
· post 3.92
Closed
Oct 30 '26
Mkt cap
$488.2M
Revenue
$14M
Q2 FY26
Revenue
$45M
FY25
vs
Compare
Closed
Oct 30 '26
MIST
Milestone Pharmaceuticals Inc.
vs
AQST
Aquestive Therapeutics, Inc.
0.73
▼
−7.26%
post 0.73
Price
3.89
▼
−3.79%
post 3.92
$90.9M
Mkt cap
$488.2M
Q2 FY26
$559,000
Revenue
$14M
Q2 FY26
—
Revenue
$45M
FY25
Change
Change
MIST
0.73
▼
−7.26%
vs
AQST
3.89
▼
−3.79%
Closed
Oct 30 '26